Curtin N - Search Results

1

Determining the Potential of DNA Damage Response (DDR) Inhibitors in Cervical Cancer Therapy.

Saha S, Rundle S, Kotsopoulos IC, Begbie J, Howarth R, Pappworth IY, Mukhopadhyay A, Kucukmetin A, Marchbank KJ, Curtin N. Saha S, et al. Among authors: curtin n. Cancers (Basel). 2022 Sep 1;14(17):4288. doi: 10.3390/cancers14174288. Cancers (Basel). 2022. PMID: 36077823 Free PMC article.

2

Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors.

Mukhopadhyay A, Elattar A, Cerbinskaite A, Wilkinson SJ, Drew Y, Kyle S, Los G, Hostomsky Z, Edmondson RJ, Curtin NJ. Mukhopadhyay A, et al. Clin Cancer Res. 2010 Apr 15;16(8):2344-51. doi: 10.1158/1078-0432.CCR-09-2758. Epub 2010 Apr 6. Clin Cancer Res. 2010. PMID: 20371688

3

Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.

Drew Y, Mulligan EA, Vong WT, Thomas HD, Kahn S, Kyle S, Mukhopadhyay A, Los G, Hostomsky Z, Plummer ER, Edmondson RJ, Curtin NJ. Drew Y, et al. J Natl Cancer Inst. 2011 Feb 16;103(4):334-46. doi: 10.1093/jnci/djq509. Epub 2010 Dec 23. J Natl Cancer Inst. 2011. PMID: 21183737

4

PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine.

Mukhopadhyay A, Curtin N, Plummer R, Edmondson RJ. Mukhopadhyay A, et al. Among authors: curtin n. BJOG. 2011 Mar;118(4):429-32. doi: 10.1111/j.1471-0528.2010.02838.x. Epub 2011 Jan 18. BJOG. 2011. PMID: 21244617 Review.

5

Defective homologous recombination in human cancers.

Cerbinskaite A, Mukhopadhyay A, Plummer ER, Curtin NJ, Edmondson RJ. Cerbinskaite A, et al. Among authors: curtin nj. Cancer Treat Rev. 2012 Apr;38(2):89-100. doi: 10.1016/j.ctrv.2011.04.015. Epub 2011 Jun 28. Cancer Treat Rev. 2012. PMID: 21715099 Review.

6

Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival.

Mukhopadhyay A, Plummer ER, Elattar A, Soohoo S, Uzir B, Quinn JE, McCluggage WG, Maxwell P, Aneke H, Curtin NJ, Edmondson RJ. Mukhopadhyay A, et al. Cancer Res. 2012 Nov 15;72(22):5675-82. doi: 10.1158/0008-5472.CAN-12-0324. Epub 2012 Oct 11. Cancer Res. 2012. PMID: 23066035 Clinical Trial.

7

The use of ovarian cancer cells from patients undergoing surgery to generate primary cultures capable of undergoing functional analysis.

O Donnell RL, McCormick A, Mukhopadhyay A, Woodhouse LC, Moat M, Grundy A, Dixon M, Kaufman A, Soohoo S, Elattar A, Curtin NJ, Edmondson RJ. O Donnell RL, et al. PLoS One. 2014 Mar 6;9(6):e90604. doi: 10.1371/journal.pone.0090604. eCollection 2014. PLoS One. 2014. PMID: 24603616 Free PMC article.

8

Poly(ADP-Ribose) Polymerase in Cervical Cancer Pathogenesis: Mechanism and Potential Role for PARP Inhibitors.

Kotsopoulos IC, Kucukmetin A, Mukhopadhyay A, Lunec J, Curtin NJ. Kotsopoulos IC, et al. Int J Gynecol Cancer. 2016 May;26(4):763-9. doi: 10.1097/IGC.0000000000000654. Int J Gynecol Cancer. 2016. PMID: 26905326 Review.

9

Targeting the ATR-CHK1 Axis in Cancer Therapy.

Rundle S, Bradbury A, Drew Y, Curtin NJ. Rundle S, et al. Cancers (Basel). 2017 Apr 27;9(5):41. doi: 10.3390/cancers9050041. Cancers (Basel). 2017. PMID: 28448462 Free PMC article. Review.

10

The Impact of p53 Dysfunction in ATR Inhibitor Cytotoxicity and Chemo- and Radiosensitisation.

Middleton FK, Pollard JR, Curtin NJ. Middleton FK, et al. Cancers (Basel). 2018 Aug 20;10(8):275. doi: 10.3390/cancers10080275. Cancers (Basel). 2018. PMID: 30127241 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

291 results

Search Page

Filters